ANZCHOG Children’s Cancer Clinical Trials Repository

Study Title
M13-833: A Phase I Study of the Safety and Pharmacokinetics of Venetoclax in Paediatric and Young Adult Patients with Relapsed or Refractory Malignancies
Protocol ID
M13-833
Condition/s
Acute Lymphoblastic Leukemia (ALL)
Acute Myeloid Leukemia (AML)
Non-Hodgkin's Lymphoma
Neuroblastoma
Diagnosis Stage
Relapse/ refractory
Sponsor
AbbVie
Collaborators
Roche-Genentech
Links
External Registry ≫
Trial Status
Closed to Recruitment
Study Type
Treatment
Phase
Phase 1
Age Eligibility
up to 25 years
International registry ID's
NCT03236857
Back to Registry
Study Title M13-833: A Phase I Study of the Safety and Pharmacokinetics of Venetoclax in Paediatric and Young Adult Patients with Relapsed or Refractory Malignancies
Protocol ID M13-833
Disease (Sub Disease) Acute Lymphoblastic Leukemia (ALL)
Acute Myeloid Leukemia (AML)
Non-Hodgkin's Lymphoma
Neuroblastoma
Diagnosis Stage Relapse/ refractory
Sponsor AbbVie
Collaborators Roche-Genentech
Links https://clinicaltrials.gov/ct2/show/NCT03236857
Trial Status Closed to Recruitment
Trial Open Date 17/08/2017
Study Type Treatment
Phase Phase 1
Age Eligibility up to 25 years
International registry ID's NCT03236857

Join our newsletter

"*" indicates required fields

This field is for validation purposes and should be left unchanged.

Email info@anzchog.org   |  

Level 6, TRF Building, Hudson Institute, 27-31 Wright St, Clayton VIC 3168

ANZCHOG acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait Islander cultures, and to Elders both past and present. We acknowledge Māori as tangata whenua of Aotearoa New Zealand and as Treaty partners with the Crown as agreed in Te Tiriti o Waitangi. 

We are committed to creating a safe and welcoming environment that embraces all backgrounds, cultures, sexualities, genders and abilities.